KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Accounts Payables (2020 - 2025)

Recursion Pharmaceuticals' Accounts Payables history spans 6 years, with the latest figure at $18.1 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 16.17% year-over-year to $18.1 million; the TTM value through Dec 2025 reached $18.1 million, down 16.17%, while the annual FY2025 figure was $18.1 million, 16.17% down from the prior year.
  • Accounts Payables reached $18.1 million in Q4 2025 per RXRX's latest filing, up from $13.9 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $25.1 million in Q1 2025 to a low of $2.1 million in Q2 2023.
  • Average Accounts Payables over 5 years is $7.8 million, with a median of $4.2 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: crashed 47.01% in 2024, then skyrocketed 516.59% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $2.8 million in 2021, then surged by 62.68% to $4.6 million in 2022, then dropped by 13.8% to $4.0 million in 2023, then soared by 446.75% to $21.6 million in 2024, then fell by 16.17% to $18.1 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Accounts Payables are $18.1 million (Q4 2025), $13.9 million (Q3 2025), and $19.3 million (Q2 2025).